Apolipoprotein E polymorphism and plasma cholesterol response to probucol.

Apolipoprotein E polymorphism and plasma cholesterol response to probucol.
复制标题

载脂蛋白 E 多态性和血浆胆固醇对普罗布考的反应。

DOI:
10.1016/0026-0495(87)90110-7
复制
发表时间:
1987
期刊:
Metabolism: clinical and experimental
影响因子:
--
通讯作者:
Davignon,J
Davignon,J
中科院分区:
--
文献类型:
--
作者:
Nestruck,AC;Bouthillier,D;Sing,CF;Davignon,J

文献摘要

参考文献

被引文献

相似文献

普罗布考已被证明是一种有效且耐受性良好的降胆固醇药物。然而,在降低胆固醇方面的反应在不同的人之间表现出了很大的差异。本研究的目的是评估载脂蛋白E基因多态性在决定这种变异中的作用。对89例已接受普罗布考(1g/d)治疗并已知载脂蛋白E表型的高胆固醇血症II型患者进行了回顾性研究。这些患者首先被分为杂合子家族性高胆固醇血症(FH)和那些被认为有其他形式的高胆固醇血症(非FH)。将两组中的个体进一步细分为IIa或IIb,允许定义四个诊断类别,FH IIa或IIb和非FH IIa或IIb。在这些班级中,反应与年龄或性别之间的关系没有显著的异质性。在校正了普罗布考治疗时间的组间异质性后,携带ϵ4等位基因和apo E3表型的个体在降低胆固醇方面的绝对变化和百分比变化均有显著差异。这些数据的诊断和载脂蛋白E基因分层的进一步对比表明,携带ϵ4等位基因的FH患者的胆固醇水平下降幅度最大。
Probucol has been shown to be an effective and well-tolerated cholesterol-lowering drug. However, response in terms of cholesterol reduction has been shown to vary significantly among individuals. The purpose of this study was to assess the role of apolipoprotein E polymorphism in determining this variation. A retrospective study of 89 hypercholesterolemic type II patients who had been treated with probucol (1 g/d) and for whom the apolipoprotein E phenotype was known was carried out. The patients were first grouped into those with heterozygous familial hypercholesterolemia (FH) and those considered to have other forms of hypercholesterolemia (non-FH). Further subclassification of the individuals in both groups as IIa or IIb, allowed the definition of four diagnostic classes, FH IIa or IIb and non-FH IIa or IIb. Among these classes there was no significant heterogeneity for the relationship between response and age or sex. After correction for between-class heterogeneity in duration of probucol treatment, comparison of individuals with the apo E3 3 phenotype with those carrying the ϵ4 allele showed significant differences in cholesterol reduction both absolute change and percent change. Further contrasts between diagnostic and apo E genotype stratifications of these data showed that the FH patients carrying the ϵ4 allele had the greatest reduction in cholesterol level.
普罗布考对人体胆固醇和脂蛋白代谢的影响。
DOI: --
发表时间: 1984
影响因子: 6.5
作者:
Kesäniemi,YA;Grundy,SM
通讯作者: Grundy,SM
基于空腹血浆甘油三酯-胆固醇比率和血浆胆固醇对对氯苯氧基异丁酸乙酯的反应,研究 II 型家族性高脂蛋白血症的异质性。
DOI: --
发表时间: 1971
期刊: Revue canadienne de biologie
影响因子: --
作者:
J. Davignon;F. Aubry;C. Noël;Y. Lapierre;M. Lafortune
通讯作者: M. Lafortune
普罗布考在治疗原发性高胆固醇血症中的用途。
DOI: --
发表时间: 1980
影响因子: 14.6
作者:
M. Enjalbert;S. Lussier‐Cacan;S. Dubreuil;J. LeLorier;J. Davignon
通讯作者: J. Davignon
普罗布考对 IIb 型高脂蛋白血症血浆脂质和脂蛋白的影响。
DOI: --
发表时间: 1980
期刊: Atherosclerosis
影响因子: 5.3
作者:
D. Hunninghake;C. Bell;L. Olson
通讯作者: L. Olson
普罗布考的药理学和毒理学。
DOI: --
发表时间: 1982
期刊:
影响因子: --
作者:
Marshall Fn
通讯作者: Marshall Fn